Ophtalmopole, Cochin Hospital, AP-HP, Assistance Publique Hôpitaux de Paris, 24 Rue Du Faubourg Saint-Jacques, 75014, Paris, France.
INSERM, UMRS1138, Team 17, From Physiopathology of Ocular Diseases to Clinical Development, Université Sorbonne Paris Cité, Centre de Recherche des Cordeliers, 15 Rue de L'Ecole de Médecine, 75006, Paris, France.
Exp Eye Res. 2019 Oct;187:107754. doi: 10.1016/j.exer.2019.107754. Epub 2019 Aug 8.
Central serous chorioretinopathy (CSCR) is part of the pachychoroid spectrum disorders, characterized by serous retinal detachments, retinal pigment epithelium alterations and dilation of choroidal vessels. No consensus exists regarding the clinical classification and the physiopathogenic mechanisms of the disease, delaying the comprehension of the most optimal treatment options. An overactivation of the mineralocorticoid receptor (MR) pathway in the choroid/retina has been suggested in CSCR. Since, MR antagonists could target the affected RPE/choroid in CSCR and have shown to act as disease modifier drugs inducing tissue remodeling in other organs (heart, kidney, vessels), we summarize here the pre-clinical and clinical evidence for using oral mineralocorticoid receptor antagonist in the treatment of CSCR.
中心性浆液性脉络膜视网膜病变（CSCR）是肥厚脉络膜疾病谱的一部分，其特征是浆液性视网膜脱离、视网膜色素上皮改变和脉络膜血管扩张。目前对于该疾病的临床分类和发病机制尚无共识，这阻碍了对最佳治疗选择的理解。有研究提示，CSCR 患者脉络膜/视网膜中醛固酮受体（MR）途径的过度激活。由于 MR 拮抗剂可作用于 CSCR 中受影响的 RPE/脉络膜，并且已被证明可作为疾病修饰药物，在其他器官（心脏、肾脏、血管）中诱导组织重塑，因此，我们在这里总结了使用口服 MR 拮抗剂治疗 CSCR 的临床前和临床证据。
